Delayed MS Decision and Trial Miss Add to Sanofi’s R&D Challenges

Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...
Pharmabiz

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis: Paris Friday, December 26, 2025, 13:00 Hrs [IST] The US Foo ...
Multiple Sclerosis News Today

Four distinct paths of disability progression emerge in relapsing MS

Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal — Update

Sanofi agreed to buy vaccine specialist Dynavax Technologies in a $2.2 billion cash deal, turning to dealmaking in a bid to move past pipeline setbacks.

Sanofi multiple sclerosis therapy rejected by the FDA

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisParis, December 24, 2025.